Literature DB >> 8254490

Differential elimination of synthetic butyric triglycerides in vivo: a pharmacokinetic study.

P Planchon1, P Pouillart, G Ronco, P Villa, F Pieri.   

Abstract

New butyrate derivatives were synthesized to investigate the residence time of potent butyric acid in vivo. These derivatives were triglycerides in which one, two, or three butyric acid molecules were bound to glycerol or to mono- and dipalmitic esters of glycerol. Pharmacokinetic studies showed that a constant plasma level of each compound was maintained for a long time; all molecules had identical volumes of distribution, but differed about their mean residence time. Triesters in which palmitic acid was present displayed no toxicity and seemed to be even more stable in the organism; this may be due to their adsorption on the tissue. Other triglycerides constituted by butyric acid and various long fatty acids may be synthesized and useful in long-term clinical treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8254490

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

1.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.

Authors:  A Saito; T Yamashita; Y Mariko; Y Nosaka; K Tsuchiya; T Ando; T Suzuki; T Tsuruo; O Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

2.  A novel dual-prodrug carried by cyclodextrin inclusion complex for the targeting treatment of colon cancer.

Authors:  Lin Chen; Yan Lin; Zijun Zhang; Ruisheng Yang; Xiaosheng Bai; Zhongbing Liu; Zhongling Luo; Meiling Zhou; Zhirong Zhong
Journal:  J Nanobiotechnology       Date:  2021-10-19       Impact factor: 10.435

3.  Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer.

Authors:  R Kuefer; M D Hofer; V Altug; C Zorn; F Genze; K Kunzi-Rapp; R E Hautmann; J E Gschwend
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.